Factors affecting potential launch of generic version of Alzheimer’s disease treatment Ebixa® (Meman

GenericsWeb, the leader in established pharmaceutical patent analysis and searching, recently published an article on Ebixa® (Memantine) based on information from its flagship product Ark Patent Intelligence. Sydney, Australia, July 2014 (PRWEB) July 17, 2014 Also known as Namenda®, the article gives a brief outline of factors affecting the potential launch of generic versions of Memantine, Merz’s N-methyl-D-aspartate antagonist. Lundbeck reported Ebixa® sales of DKK 2.1 billion (USD 420 million) in 2013. In the US, Forest reported Namenda® sales of USD 1.5 billion duri
Contributor
PR Web
PR Web
Lanham, Maryland
Law Marketing
1.800.345.5572
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Download

Related Documents in PR Web
MCLE Sales

Categories